S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ALDX Aldeyra Therapeutics Inc

4.10

0.165 (4.19%)

27 Apr 2024 - Closed

Delayed by 15 minutes

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Aldeyra Therapeutics Charts.

Aldeyra Therapeutics Inc News

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
Thursday 25 April 2024 (3 days ago) • Business Wire

Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
Thursday 18 April 2024 (1 week ago) • Business Wire

Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Thursday 28 March 2024 (1 month ago) • Business Wire

Form S-3 - Registration statement under Securities Act of 1933
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 8 March 2024 (2 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Tuesday 6 February 2024 (3 months ago) • Business Wire

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Tuesday 30 January 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 4 January 2024 (4 months ago) • Edgar (US Regulatory)

Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases
Thursday 4 January 2024 (4 months ago) • Business Wire

Form 8-K - Current report
Friday 22 December 2023 (4 months ago) • Edgar (US Regulatory)

More Aldeyra Therapeutics Inc News Articles

Gold vs US Dollar

Newcrest Mining

Westpac Banking

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions